Literature DB >> 10937060

Expression of the five different somatostatin receptor subtypes in endocrine cells of the pancreas.

G M Portela-Gomes1, M Stridsberg, L Grimelius, K Oberg, E T Janson.   

Abstract

Knowledge concerning tissue-specific expression of the five somatostatin receptor subtypes is of great importance in understanding their physiological function. We developed rabbit polyclonal antibodies specific for each human somatostatin receptor subtype and report our results concerning the expression in normal endocrine pancreatic cells. The antibodies were produced by immunizing rabbits with fragments specific for the five cloned somatostatin receptor subtypes. Colocalization of these somatostatin receptors with the four major islet hormones--insulin, glucagon, somatostatin, and pancreatic polypeptide--was studied in normal human endocrine pancreatic cells, using double-immunofluorescence staining. High expression of somatostatin receptor subtypes 1, 3, and 4 was found in all endocrine pancreatic cells. Somatostatin receptor subtype 2 was frequently expressed in alpha and beta cells, whereas expression was low in pancreatic polypeptide cells and intermediate in delta cells. Somatostatin receptor subtype 5 was expressed in most beta and delta cells but almost absent in alpha and pancreatic polypeptide cells. There is a variability in the normal expression of somatostatin receptor subtypes among the different human endocrine pancreatic cells. Knowledge of this expression and the physiological function mediated by these receptors will be valuable in the future when considering treatment of endocrine disorders.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10937060     DOI: 10.1097/00129039-200006000-00007

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  23 in total

1.  Somatostatin receptor subtypes in hormone-refractory (castration-resistant) prostatic carcinoma.

Authors:  Roberta Mazzucchelli; Doriana Morichetti; Marina Scarpelli; Aldo V Bono; Antonio Lopez-Beltran; Liang Cheng; Ziya Kirkali; Rodolfo Montironi
Journal:  Asian J Androl       Date:  2010-12-13       Impact factor: 3.285

2.  Physiological expression of pancreatic somatostatin receptors in 99mTc-HYNIC-TOC scintigraphy.

Authors:  L de la Cueva; P Lloro; M J Sangrós; L López Vélez; P Navarro; L Sarria; S Álvarez; D Abós
Journal:  Clin Transl Oncol       Date:  2017-01-31       Impact factor: 3.405

3.  System-level control to optimize glucagon counterregulation by switch-off of α-cell suppressing signals in β-cell deficiency.

Authors:  Leon S Farhy; Anthony L McCall
Journal:  J Diabetes Sci Technol       Date:  2009-01

Review 4.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

5.  Models of glucagon secretion, their application to the analysis of the defects in glucagon counterregulation and potential extension to approximate glucagon action.

Authors:  Leon S Farhy; Anthony L McCall
Journal:  J Diabetes Sci Technol       Date:  2010-11-01

Review 6.  Optimizing reduction in basal hyperglucagonaemia to repair defective glucagon counterregulation in insulin deficiency.

Authors:  L S Farhy; A L McCall
Journal:  Diabetes Obes Metab       Date:  2011-10       Impact factor: 6.577

7.  Association Between Somatostatin Receptor Expression and Clinical Outcomes in Neuroendocrine Tumors.

Authors:  Zhi Rong Qian; Tingting Li; Monica Ter-Minassian; Juhong Yang; Jennifer A Chan; Lauren K Brais; Yohei Masugi; Arunthathi Thiaglingam; Nichole Brooks; Reiko Nishihara; Mireille Bonnemarie; Atsuhiro Masuda; Kentaro Inamura; Sun A Kim; Kosuke Mima; Yasutaka Sukawa; Ruoxu Dou; Xihong Lin; David C Christiani; Fabien Schmidlin; Charles S Fuchs; Umar Mahmood; Shuji Ogino; Matthew H Kulke
Journal:  Pancreas       Date:  2016-11       Impact factor: 3.327

8.  Neuropeptide Y and somatostatin inhibit insulin secretion through different mechanisms.

Authors:  Tara A Schwetz; Alessandro Ustione; David W Piston
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-12-04       Impact factor: 4.310

9.  Amplification of pulsatile glucagon counterregulation by switch-off of alpha-cell-suppressing signals in streptozotocin-treated rats.

Authors:  Leon S Farhy; Zhongmin Du; Qiang Zeng; Paula P Veldhuis; Michael L Johnson; Kenneth L Brayman; Anthony L McCall
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-06-24       Impact factor: 4.310

10.  Differential expression of the five somatostatin receptor subtypes in human benign and malignant insulinomas - predominance of receptor subtype 4.

Authors:  Guida Maria Portela-Gomes; Mats Stridsberg; Lars Grimelius; Otto Rorstad; Eva Tiensuu Janson
Journal:  Endocr Pathol       Date:  2007       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.